(Q34643734)

3 August 2017

Next-generation treatments for mental disorders (English)

1 reference

3 August 2017

Thomas R Insel

1

1 reference

PubMed ID

23052292

3 August 2017

language of work or name

English

0 references

publication date

1 October 2012

1 reference

Science Translational Medicine

3 August 2017

1 reference

3 August 2017

4

1 reference

3 August 2017

155

1 reference

3 August 2017

155ps19

1 reference

Cure therapeutics and strategic prevention: raising the bar for mental health research

3 August 2017

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Is pharma running out of brainy ideas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Prevalence and treatment of mental disorders, 1990 to 2003

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

The size and burden of mental disorders and other disorders of the brain in Europe 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Medicine. What are the right targets for psychopharmacology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Genomewide association studies and assessment of the risk of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Initial impact of the sequencing of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Copy number variation in human health, disease, and evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Strong association of de novo copy number mutations with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Reengineering translational science: the time is right

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Mechanisms of disease: genetic causes of familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Somatic retrotransposition alters the genetic landscape of the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Somatic activation of AKT3 causes hemispheric developmental brain malformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Genome-wide association study identifies five new schizophrenia loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Interplay between DISC1 and GABA signaling regulates neurogenesis in mice and risk for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Protein interactome reveals converging molecular pathways among autism disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Disruption of neurexin 1 associated with autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Fibroblast growth factor-2 (FGF2) augmentation early in life alters hippocampal development and rescues the anxiety phenotype in vulnerable animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Alterations in 5-HT1B receptor function by p11 in depression-like states

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Macrophage migration inhibitory factor mediates the antidepressant actions of voluntary exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Neuritin produces antidepressant actions and blocks the neuronal and behavioral deficits caused by chronic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Discovery of a proneurogenic, neuroprotective chemical

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Neurogenesis and affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

21 January 2018

Rethinking schizophrenia

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Modelling schizophrenia using human induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Astrocyte signaling controls spike timing-dependent depression at neocortical synapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Signaling pathways underlying the rapid antidepressant actions of ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Optogenetics and psychiatry: applications, challenges, and opportunities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Somatic treatments for mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Computerized cognitive training restores neural activity within the reality monitoring network in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Attention bias modification treatment for pediatric anxiety disorders: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Outcome predictors in guided and unguided self-help for social anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Frontal theta cordance predicts 6-month antidepressant response to subcallosal cingulate deep brain stimulation for treatment-resistant depression: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Research domain criteria (RDoC): toward a new classification framework for research on mental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Prevention of depression among Icelandic adolescents: a 12-month follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

How to improve R&D productivity: the pharmaceutical industry's grand challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Drug development: Raise standards for preclinical cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Believe it or not: how much can we rely on published data on potential drug targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Leveraging crowdsourcing to facilitate the discovery of new medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Reflections on the Innovative Medicines Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative US survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3004873

10.1126/SCITRANSLMED.3004873

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

23052292